Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adamis Pharmaceuticals Corporation

http://www.adamispharmaceuticals.com/

Latest From Adamis Pharmaceuticals Corporation

What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates

Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.

Approvals Drug Review

Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization

Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.

Financing StartUps and SMEs

China Rings In New Year With Major Deals, Record IPOs And Trends To Watch

From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.

China Commercial

Migraine & Hepatitis B Prevention Products Among New EU Filings

The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.

Europe Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Biosyn Inc.
    • Cellegy Holdings Inc
    • US Compounding, Inc.
UsernamePublicRestriction

Register